OTSUKA PHARMACEUTICAL CO., LTD.
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Public, Subsidiary
- Established
- 1964-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.otsuka.co.jp
Study of Aripiprazole in Patients With Schizophrenia- Effects on Glucose Metabolism-
Phase 4
Completed
- Conditions
- Schizophrenia
- First Posted Date
- 2006-10-25
- Last Posted Date
- 2014-02-12
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 111
- Registration Number
- NCT00392197
A Dose-finding Study of OPC-6535 in Patients With Active Crohn's Disease
Phase 2
Terminated
- Conditions
- Crohn Disease
- First Posted Date
- 2006-04-24
- Last Posted Date
- 2021-02-15
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 29
- Registration Number
- NCT00317369
A Dose-finding Study of OPC-6535 in Patients With Active Ulcerative Colitis
Phase 2
Terminated
- Conditions
- Colitis, Ulcerative
- First Posted Date
- 2006-04-24
- Last Posted Date
- 2021-04-30
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 43
- Registration Number
- NCT00317356
A Dose-finding Study of OPC-41061 in Treatment of Cardiac Edema (Congestive Heart Failure)
Phase 2
Completed
- Conditions
- Heart Failure, CongestiveEdema
- First Posted Date
- 2005-10-06
- Last Posted Date
- 2013-12-25
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 122
- Registration Number
- NCT00234104
- Locations
- 🇯🇵
Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan
Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2)
- First Posted Date
- 2005-10-06
- Last Posted Date
- 2011-06-10
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 2800
- Registration Number
- NCT00234065
- Locations
- 🇯🇵
Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan
Dose-response Study of OPC-12759 Ophthalmic Suspension
Phase 2
Completed
- Conditions
- Dry Eye Syndromes
- Interventions
- Drug: 0.5% OPC-12759Drug: 1% OPC-12759Drug: 2% OPC-12759Drug: placebo
- First Posted Date
- 2005-10-06
- Last Posted Date
- 2014-02-28
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 290
- Registration Number
- NCT00234078
- Locations
- 🇯🇵
Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan
Exploratory Study for Dry Mouth in Patients With Sjögren's Syndrome
Phase 2
Completed
- Conditions
- XerostomiaSjogren's Syndrome
- First Posted Date
- 2005-10-05
- Last Posted Date
- 2021-06-04
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 104
- Registration Number
- NCT00233363
- Locations
- 🇯🇵
Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan
Post-marketing Clinical Study of Rebamipide in Patients With Gastric Ulcer
Phase 4
Completed
- Conditions
- Stomach Ulcer
- First Posted Date
- 2005-10-05
- Last Posted Date
- 2021-06-04
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 301
- Registration Number
- NCT00233389
- Locations
- 🇯🇵
Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan
© Copyright 2025. All Rights Reserved by MedPath